Kidney Week 2026: Exhibitor Spotlight Schedule
Thursday, October 22 - October 24
Colorado Convention Center, Exhibit Hall A
Join your colleagues for the latest advances in nephrology practices, products, services, and technologies presented in three theaters on the exhibit hall floor. Seating is limited and available on a first-come, first-served basis to fully registered Kidney Week participants only. Exhibitor Spotlights are not CE (continuing education) activities.
The 10:15 a.m. presentations include breakfast. All other presentations include lunch.
Thursday, Octobrer 22
10:15-11:00 a.m.
Experiencing HighVolumeHDF: Perspectives from U.S. Prescribers and Patients
Presented by Fresenius Medical Care
11:00-11:45 a.m.
Advancing Hypertension Care: The Role of Renal Denervation in Nephrology Practice
Presented by Medtronic
11:30 a.m.-12:15 p.m.
Consensus and Clinical Implications: Interpreting the Proposed KDIGO Guidelines
Presented by Vantive Healthcare
12:00-12:45 p.m.
Moving Upstream in IgA Nephropathy: From Pathogenic Drivers to Patient Outcomes
Presented by Vertex Pharmaceuticals
12:30-1:15 p.m.
Investigational Treatment Mechanisms in FSGS and Complement-Mediated Kidney Diseases
Presented by Akebia Therapeutics
1:00-1:45 p.m.
Advancing the Treatment Paradigm in IgAN
Presented by Vera Therapeutics
Friday, October 23
10:15-11:00 a.m.
Why Aldosterone Matters for Kidney Outcomes in CKM Syndrome
Presented by Boehringer Ingelheim
11:00-11:45 a.m.
Expanding Perspectives in Hyperphosphatemia Treatment; A Different Approach
Presented by Ardelyx, Inc.
11:30 a.m.-12:15 p.m.
Evaluating the Heterogeneity of IgAN: Evolving Strategies for Treatment
Presented by Novartis Pharmaceuticals
12:00-12:45 p.m.
Beyond B-cells: Pioneering Plasmablast and Plasma Cell Targeting in IgAN and PMN
Presented by Biogen
12:30-1:15 p.m.
Expanded HD with ELISIO-HX: Transforming US Dialysis Treatment
Presented by NIPRO
1:00-1:45 p.m.
A Treatment for Two Rare Glomerular Diseases: C3G and Primary IC-MPGN
Presented by Biogen
Saturday, October 24
10:15-11:00 a.m.
Connecting the Dots in IgAN: Complement Nexus in Inflammation and Nephron Loss
Presented by Alexion, AstraZeneca Rare Disease
11:00-11:45 a.m.
The Next Era in the Treatment of Hypertension
Presented by Idorsia
11:30 a.m.-12:15 p.m.
VOYXACT® (sibeprenlimab): Managing Adult Patients With Primary IgAN at Risk for Disease Progression
Presented by Otsuka America Pharmaceutical, Inc.
12:00-12:45 p.m.
A Dual-Acting Approach in FSGS and IgAN
Presented by Travere Therapeutics
12:30-1:15 p.m.
Expert-led Review: Identifying Treatment Opportunities for Patients with Lupus Nephritis
Presented by Genentech
1:00-1:45 p.m.
A Novel Aldosterone-Targeted Treatment for Patients with Uncontrolled Hypertension
Presented by AstraZeneca
Additional information, if provided by the supporter, is available by clicking on the presentation title.